Phthalimido derivatives and a process for their preparation
AssigneeHoffmann-La Roche Inc.
InventorsAndrea Cesura, Rosa Maria Rodriguez Sarmiento, Andrew William Thomas, Rene Wyler
Life of this patent
Estimating the term…
Abstract
This invention relates to phthalimido derivatives of the formula wherein X is —N═ or —CH═, and R1 to R4 and m are as defined in the specification, as well as their pharmaceutically acceptable salts. The invention further relates to pharmaceutical compositions containing these compounds, a method of treating a disease by administering a therapeutically effective amount of at least one of these compounds, and a process for their preparation for the treatment or prevention of diseases in which MAO-B inhibitors might be beneficial.
Claims14
A compound of the formula
- wherein
- X is —N═ or —CH═;
- R1 is —CO—NR5R6;
- —CHR7—(CH2)n—CO—NR5R6;
- —(CH2)n—NR5R6;
- —(CH2)n—COOR8;
- —(CH2)n—CN;
- —CHR7—(CH2)n—CF3;
- —(CH2)n—NH—COR9;
- —(CH2)n—NH—COOR8;
- a heterocyclic ring-containing group selected from —(CH2)n-piperidinyl, —(CH2)n-morpholinyl, —(CH2)n-tetrahydrofuranyl;
- —(CH2)n-thiophenyl or —(CH2)n-isoxazolyl, wherein the heterocyclic ring may be substituted by C1-C6-alkyl;
- a phenyl;
- —(CH2)n-phenyl, wherein the phenyl ring may be substituted by halogen or halogen-(C1-C6)-alkyl;
- —(CH2)p—OR8;
- —(CH2)p—SR8;
- —(CH2)p—SO—R9;
- or
- —(CH2)n—CS—NR5R6;
- R2 is hydrogen;
- C1-C6-alkyl;
- —(CH2)p—OR10;
- —(CH2)p—SR10;
- or benzyl;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is halogen, halogen-(C1-C6)-alkyl, cyano, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are independently from each other hydrogen or C1-C6-alkyl;
- R7 is hydrogen, hydroxy or C1-C6-alkoxy;
- R8 is hydrogen or C1-C6-alkyl;
- R9 is C1-C6-alkyl;
- R10 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition containing one or more compounds of the formula
- wherein
- X is —N═ or —CH═;
- R1 is —CO—NR5R6;
- —CHR7—(CH2)n—CO—NR5R6;
- —(CH2)n—NR5R6;
- —(CH2)n—COOR8;
- —(CH2)n—CN;
- —CHR7—(CH2)n—CF3;
- —(CH2)n—NH—COR9;
- —(CH2)n—NH—COOR8;
- a heterocyclic ring-containing group selected from —(CH2)n-piperidinyl, —(CH2)n-morpholinyl, —(CH2)n-tetrahydrofuranyl;
- —(CH2)n-thiophenyl or —(CH2)n-isoxazolyl, wherein the heterocyclic ring may be substituted by C1-C6-alkyl;
- a phenyl;
- —(CH2)n-phenyl, wherein the phenyl ring may be substituted by halogen or halogen-(C1-C6)-alkyl;
- —(CH2)p—OR8;
- —(CH2)p—SR8;
- —(CH2)p—SO—R9;
- or
- —(CH2)n—CS—NR5R6;
- R2 is hydrogen;
- C1-C6-alkyl;
- —(CH2)p—OR10;
- —(CH2)p—SR10;
- or benzyl;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is halogen, halogen-(C1-C6)-alkyl, cyano, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are independently from each other hydrogen or C1-C6-alkyl;
- R7 is hydrogen, hydroxy or C1-C6-alkoxy;
- R8 is hydrogen or C1-C6-alkyl;
- R9 is C1-C6-alkyl;
- R10 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.
Dependencies are inferred from the claim text.